Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
7(64%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
6
55%
Ph phase_4
2
18%
Ph not_applicable
1
9%
Ph phase_3
2
18%

Phase Distribution

0

Early Stage

6

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
6(54.5%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
2(18.2%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

11

all time

Status Distribution
Active(9)
Completed(1)
Other(1)

Detailed Status

Recruiting7
Not yet recruiting2
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
7
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 26 (54.5%)
Phase 32 (18.2%)
Phase 42 (18.2%)
N/A1 (9.1%)

Trials by Status

completed19%
not_yet_recruiting218%
recruiting764%
unknown19%

Recent Activity

7 active trials
Showing 5 of 11
recruitingphase_2

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

NCT05903092
recruitingphase_2

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

NCT06536868
not_yet_recruitingphase_2

A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer

NCT07538271
recruitingphase_3

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06711900
recruitingphase_2

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

NCT05613413
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05903092Phase 2

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Recruiting
NCT06536868Phase 2

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Recruiting
NCT07538271Phase 2

A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer

Not Yet Recruiting
NCT06711900Phase 3

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting
NCT05613413Phase 2

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Recruiting
NCT06868836Phase 2

A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer

Recruiting
NCT06292286Not Applicable

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer

Recruiting
NCT06931145Phase 4

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Not Yet Recruiting
NCT06357598Phase 4

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer

Recruiting
NCT05302011Phase 2

Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Completed
NCT03991403Phase 3

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11